Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Sell
8
TKPHF Quote, Financials, Valuation and Earnings
Last price:
$26.30
Seasonality move
:
1.35%
Day range:
$26.30 - $26.30
52-week range:
$23.80 - $32.13
Dividend yield:
5.04%
P/E ratio:
60.26x
P/S ratio:
1.41x
P/B ratio:
0.89x
Volume:
--
Avg. volume:
10.9K
1-year change:
1.3%
Market cap:
$41.1B
Revenue:
$30.1B
EPS (TTM):
$0.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical
|
$7.6B | -- | 2.48% | -- | -- |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical
|
$26.30 | -- | $41.1B | 60.26x | $0.65 | 5.04% | 1.41x |
|
AMGXF
AnGes
|
$0.36 | -- | $117.8M | -- | $0.00 | 0% | 22.97x |
|
HLOSF
Healios KK
|
$2.25 | -- | $228.3M | -- | $0.00 | 0% | 54.40x |
|
PPTDF
PeptiDream
|
$13.53 | -- | $1.8B | 16.80x | $0.00 | 0% | 5.80x |
|
SOLTF
Nxera Pharma
|
$5.91 | -- | $531.3M | -- | $0.00 | 0% | 2.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical
|
39.43% | -1.038 | 61.12% | 0.45x |
|
AMGXF
AnGes
|
-- | 1.309 | -- | 1.28x |
|
HLOSF
Healios KK
|
51.17% | -2.492 | 6.95% | 1.11x |
|
PPTDF
PeptiDream
|
25.74% | 0.548 | 5.48% | 4.62x |
|
SOLTF
Nxera Pharma
|
48.1% | 1.902 | 78.18% | 2.83x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TKPHF
Takeda Pharmaceutical
|
$4.4B | -$491.4M | 0.89% | 1.49% | -5.41% | $854.8M |
|
AMGXF
AnGes
|
$368.5K | -$8.2M | -33.92% | -33.92% | -741.83% | -- |
|
HLOSF
Healios KK
|
$59K | -$4.9M | -85.83% | -196.15% | -1239.47% | -$5.1M |
|
PPTDF
PeptiDream
|
$9.6M | -$9M | 23.58% | 34.1% | -29.18% | -$69.4M |
|
SOLTF
Nxera Pharma
|
$33M | -$14.4M | -4.28% | -8.65% | -28.7% | -$14.8M |
Takeda Pharmaceutical vs. Competitors
-
Which has Higher Returns TKPHF or AMGXF?
AnGes has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -737.34%. Takeda Pharmaceutical's return on equity of 1.49% beat AnGes's return on equity of -33.92%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical63.73% -$0.43 $76.5B AMGXFAnGes33.2% -$0.03 $21.5M -
What do Analysts Say About TKPHF or AMGXF?
Takeda Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than AnGes, analysts believe Takeda Pharmaceutical is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical0 0 0 AMGXFAnGes0 0 0 -
Is TKPHF or AMGXF More Risky?
Takeda Pharmaceutical has a beta of 0.211, which suggesting that the stock is 78.877% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TKPHF or AMGXF?
Takeda Pharmaceutical has a quarterly dividend of $0.65 per share corresponding to a yield of 5.04%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or AMGXF?
Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than AnGes quarterly revenues of $1.1M. Takeda Pharmaceutical's net income of -$676.5M is lower than AnGes's net income of -$8.2M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 60.26x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.41x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical1.41x 60.26x $6.9B -$676.5M AMGXFAnGes22.97x -- $1.1M -$8.2M
-
Which has Higher Returns TKPHF or HLOSF?
Healios KK has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -6742.11%. Takeda Pharmaceutical's return on equity of 1.49% beat Healios KK's return on equity of -196.15%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical63.73% -$0.43 $76.5B HLOSFHealios KK23.68% -$0.18 $26.9M -
What do Analysts Say About TKPHF or HLOSF?
Takeda Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical0 0 0 HLOSFHealios KK0 0 0 -
Is TKPHF or HLOSF More Risky?
Takeda Pharmaceutical has a beta of 0.211, which suggesting that the stock is 78.877% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TKPHF or HLOSF?
Takeda Pharmaceutical has a quarterly dividend of $0.65 per share corresponding to a yield of 5.04%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or HLOSF?
Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Healios KK quarterly revenues of $249.2K. Takeda Pharmaceutical's net income of -$676.5M is lower than Healios KK's net income of -$16.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 60.26x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.41x versus 54.40x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical1.41x 60.26x $6.9B -$676.5M HLOSFHealios KK54.40x -- $249.2K -$16.8M
-
Which has Higher Returns TKPHF or PPTDF?
PeptiDream has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -24.41%. Takeda Pharmaceutical's return on equity of 1.49% beat PeptiDream's return on equity of 34.1%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical63.73% -$0.43 $76.5B PPTDFPeptiDream34.69% -$0.05 $493M -
What do Analysts Say About TKPHF or PPTDF?
Takeda Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical0 0 0 PPTDFPeptiDream0 0 0 -
Is TKPHF or PPTDF More Risky?
Takeda Pharmaceutical has a beta of 0.211, which suggesting that the stock is 78.877% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.312%.
-
Which is a Better Dividend Stock TKPHF or PPTDF?
Takeda Pharmaceutical has a quarterly dividend of $0.65 per share corresponding to a yield of 5.04%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or PPTDF?
Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than PeptiDream quarterly revenues of $27.8M. Takeda Pharmaceutical's net income of -$676.5M is lower than PeptiDream's net income of -$6.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 60.26x while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.41x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical1.41x 60.26x $6.9B -$676.5M PPTDFPeptiDream5.80x 16.80x $27.8M -$6.8M
-
Which has Higher Returns TKPHF or SOLTF?
Nxera Pharma has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -11.44%. Takeda Pharmaceutical's return on equity of 1.49% beat Nxera Pharma's return on equity of -8.65%.
Company Gross Margin Earnings Per Share Invested Capital TKPHFTakeda Pharmaceutical63.73% -$0.43 $76.5B SOLTFNxera Pharma75.69% -$0.06 $863.6M -
What do Analysts Say About TKPHF or SOLTF?
Takeda Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TKPHFTakeda Pharmaceutical0 0 0 SOLTFNxera Pharma0 0 0 -
Is TKPHF or SOLTF More Risky?
Takeda Pharmaceutical has a beta of 0.211, which suggesting that the stock is 78.877% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.648%.
-
Which is a Better Dividend Stock TKPHF or SOLTF?
Takeda Pharmaceutical has a quarterly dividend of $0.65 per share corresponding to a yield of 5.04%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TKPHF or SOLTF?
Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Takeda Pharmaceutical's net income of -$676.5M is lower than Nxera Pharma's net income of -$5M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 60.26x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.41x versus 2.96x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TKPHFTakeda Pharmaceutical1.41x 60.26x $6.9B -$676.5M SOLTFNxera Pharma2.96x -- $43.6M -$5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Where Will Cameco Stock Be in 5 Years?
Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 47x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
84
SBET alert for May 30
SharpLink Gaming [SBET] is down 3.17% over the past day.
Buy
55
RGC alert for May 30
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Buy
73
CTEV alert for May 30
Claritev [CTEV] is up 7.82% over the past day.
